MADRIGAL PHARMACEUTICALS, INC. Adjustments to Additional Paid in Capital, Warrant Issued
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Adjustments to Additional Paid in Capital, Warrant Issued of $860.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2026-02-19
- MADRIGAL PHARMACEUTICALS, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2023-09-30 was $121.00K.
- MADRIGAL PHARMACEUTICALS, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2023-06-30 was $195.00K, a 68.65% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2023-03-31 was $544.00K.
- MADRIGAL PHARMACEUTICALS, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2022-06-30 was $622.00K.
- MADRIGAL PHARMACEUTICALS, INC. adjustments to additional paid in capital, warrant issued for fiscal 2023 was $860.00K, a 38.26% increase from fiscal 2022.
- MADRIGAL PHARMACEUTICALS, INC. adjustments to additional paid in capital, warrant issued for fiscal 2022 was $622.00K.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 6 month | Adjustments to Additional Paid in Capital, Warrant Issued 9 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month |
|---|---|---|---|---|
| 2023-12-31 | $860.00K 10-K · filed 2026-02-19 | |||
| 2023-09-30 | $121.00K 10-Q · filed 2024-10-31 | $316.00K derived: sum of 2 quarters · filed 2024-10-31 | $860.00K derived: sum of 3 quarters · filed 2024-10-31 | |
| 2023-06-30 | $195.00K 10-Q · filed 2024-10-31 | $739.00K derived: sum of 2 quarters · filed 2024-10-31 | ||
| 2023-03-31 | $544.00K 10-Q · filed 2024-10-31 | |||
| 2022-12-31 | $622.00K 10-K · filed 2025-02-26 | |||
| 2022-06-30 | $622.00K 10-Q · filed 2023-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |